Neurocrine Biosciences (NBIX) Capital Expenditures Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 32.28% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 3,566.67% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 113.56% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -14.95% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -21.54% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -59.55% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -84.04% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -76.65% |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | 4,261.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.95% |
| Dec 31, 2025 | 357.53% |
| Sep 30, 2025 | -379.01% |
| Jun 30, 2025 | -42.40% |
| Mar 31, 2025 | 872.73% |
| Dec 31, 2024 | -73.36% |
| Sep 30, 2024 | 156.25% |
| Jun 30, 2024 | 47.62% |
| Mar 31, 2024 | 83.33% |
| Dec 31, 2023 | 73.42% |
| Sep 30, 2023 | 8.28% |
| Jun 30, 2023 | 67.05% |
| Mar 31, 2023 | -92.11% |
| Dec 31, 2022 | 225.40% |
| Sep 30, 2022 | -227.64% |
| Jun 30, 2022 | 482.61% |
| Mar 31, 2022 | 68.89% |
| Dec 31, 2021 | -152.00% |
| Sep 30, 2021 | 123.64% |
| Jun 30, 2021 | -475.00% |